Company news: Vivus

Share this article:
Vivus announced Tuesday that the FDA has pushed back the review date for its weight-loss drug to July 17. The phentermine-topiramate combination, which got the thumbs-up from an FDA advisory panel in February, was slated to go for a full agency evaluation April 17. The company said in a statement that the FDA wanted more time to review the Risk Evaluation and Mitigation Strategy Vivus had proposed. That strategy is an expansion of the one Vivus  outlined in February. The initial Vivus proposal recommended patient surveys, a patient-provider agreement, pharmacy certification and limiting the drug's distribution to 10 or fewer mail-order pharmacies, among other measures. The drug's risks include memory loss and birth defects, which were among the reasons for the agency's 2010 rejection of the drug.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.